We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Transapical Access Device Facilitates Structural Heart Disease Procedures

By HospiMedica International staff writers
Posted on 17 Aug 2016
A novel transapical access and closure device helps enter the left ventricular cavity for delivery of interventional instruments.

The Permaseal device is designed to allow surgeons to access and close the left ventricle reliably, and without suturing the myocardium, in a range of minimally invasive cardiac procedures, including transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), and patent foramen ovale (PFO). The device employs PolyCor anchoring technology, which simultaneously deploys eight anchors, all connected together by a suture, into the heart tissue at high velocities, slicing open an access hole.

Image: The Permaseal device (Photo courtesy of Micro Interventional Devices).
Image: The Permaseal device (Photo courtesy of Micro Interventional Devices).

Once the procedure has been completed and the access hole needs to be sealed, the threaded suture loop is pulled upon, and the anchors are drawn together, like a purse string. In a clinical study to validate the device, Permaseal shortened operating time and hospital stay, reduced adverse events (including transfusion needs), and reduced 12-month mortality and stroke rates to zero. The Permaseal device and PolyCor anchoring technology are products of Micro Interventional Devices (MID; Newtown, PA, USA), and have been approved by the U.S. Food and Drug Administration (FDA).

“Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures. We are excited that this technology is now available to our U.S. and European surgeons and their patients,” said Michael Whitman, President and CEO of MID. “In the near future, PolyCor and MyoLast technologies will be utilized in a broad range of proprietary, catheter-based products addressing unmet needs in tricuspid repair, mitral repair, and mitral valve fixation. MID's technology platform enables open-surgical procedures to be performed percutaneously.”

Heart muscle is friable, and tends to tear along natural cleavage planes. As a result, if a slit is made in the myocardium, it begins to tear away from the edge of the incision. The transapical approach is used to safely access the interior of the heart by using a coring device to create a round access port. After the procedure, the tissues are pulled together and sewn, holding the apex together until it heals and fills with scar tissue.

Related Links:
Micro Interventional Devices


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Cannulating Sphincterotome
TRUEtome
New
Hospital Bed
Alphalite

Latest Surgical Techniques News

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Novel Sensory System Enables Real-Time Intra-Articular Pressure Monitoring

Endoscopic Surgical System Enables Remote Robot-Assisted Laparoscopic Hysterectomy